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https://doi.org/10.1016/j.cell.2020.05.027SUMMARYCOVID-19 has spread worldwide since 2019 and is now a severe threat to public health. We previously iden-
tified the causative agent as a novel SARS-related coronavirus (SARS-CoV-2) that uses human angiotensin-
converting enzyme 2 (hACE2) as the entry receptor. Here, we successfully developed a SARS-CoV-2 hACE2
transgenic mouse (HFH4-hACE2 in C3B6 mice) infection model. The infected mice generated typical intersti-
tial pneumonia and pathology that were similar to those of COVID-19 patients. Viral quantification revealed
the lungs as the major site of infection, although viral RNA could also be found in the eye, heart, and brain
in some mice. Virus identical to SARS-CoV-2 in full-genome sequences was isolated from the infected
lung and brain tissues. Last, we showed that pre-exposure to SARS-CoV-2 could protect mice from severe
pneumonia. Our results show that the hACE2 mouse would be a valuable tool for testing potential vaccines
and therapeutics.INTRODUCTION
In December 2019, a coronavirus disease (named as COVID-19
later) was reported in Wuhan city, which rapidly spread
throughout China and then to many other countries in the world
(Li et al., 2020a; Zhu et al., 2020b). TheWorldHealthOrganization
(WHO) declared COVID-19 as a pandemic onMarch 11, 2020. As
of April 26, 2020, 2,804,796 patients were confirmed from more
than200countries or areas, leavingmore than193,710casualties
(WHO, 2020).We andother groups quickly identified the etiologic
agent as a severe acute respiratory syndrome-related coronavi-
rus (SARSr-CoV), named SARS-CoV-2 (Gorbalenya AE, 2020;
Zhou et al., 2020; Zhu et al., 2020a). Hospital-admitted patients
exhibited symptoms of pneumonia with abnormal findings in
chestCTscans. Typical signsof diseases, including fever, cough,
dyspnea, bilateral lung infiltration, and lymphopenia, were similar
to that of SARS and Middle East respiratory syndrome (MERS)
patients (de Wit et al., 2016; Guan et al., 2020).
Coronaviruses are enveloped non-segmented positive-sense
RNA viruses. There are four coronavirus genera, Alphacorona-50 Cell 182, 50–58, July 9, 2020 ª 2020 Elsevier Inc.virus, Betacoronavirus, Deltacoronavirus, and Gammacoronavi-
rus, in the subfamily Coronavirinae belonging to the family Co-
ronaviridae. Human coronaviruses belong to the genera
Alphacoronavirus and Betacoronavirus and usually cause mild
respiratory illness except for the two highly pathogenic viruses,
SARS-CoV and MERS-CoV, which cause a severe respiratory
syndrome in humans (Cui et al., 2019). Thus, SARS-CoV-2 is
the seventh human coronavirus and third highly pathogenic co-
ronavirus identified. The SARS-CoV-2 shares 79.5% nt
sequence identity with SARS-CoV-BJ01 and uses the same re-
ceptor, angiotensin-converting enzyme 2 (ACE2), for entry into
cells (Hoffmann et al., 2020; Letko et al., 2020; Zhou et al.,
2020). A previous study demonstrated that the SARS-CoV
wild type replicated poorly in mice, requiring mouse adaptation
by serial passage or the development of transduced or trans-
genic mouse models expressing the human ACE2 (Frieman
et al., 2012; Menachery et al., 2016; Roberts et al., 2007; Tseng
et al., 2007; Yang et al., 2007). Despite receptor-binding
domain (RBD) structure homology between SARS-CoV-2 and
SARS-CoV, several published SARS-CoV RBD monoclonal
Figure 1. Experiment Scheme and Body-
Weight Changes in SARS-CoV-2-Infected
HFH4-hACE2 Mice
(A) Twenty-four HFH4-hACE2 mice were intrana-
sally infected with 3 3 104 TCID50 virus each and
sacrificed to collect tissue and blood samples at 1,
3, 5, and 7 days post-infection (DPI). Mouse body
weights were monitored for up to 7 days. Each dot
represents one mouse at the indicated time point.
One mouse showed a rapid body weight decrease
with dyspnea beginning on day 2 and then recov-
ered (green dot). Infected mice that died showed
noticeable body weight decreases from day 4 to 6
(red dot).
(B) Mock-infected (blue dot) and survived mice
(black dot) demonstrated normal statuses. The
dotted lines represent the fitted curve of each co-
lor-indicated group.
See also Figure S1 and Tables S1 and S2.
ll
Articleantibodies have been unable to neutralize SARS-CoV-2
(Walls et al., 2020; Wrapp et al., 2020), suggesting limited
cross-neutralization protection between the two viruses.
Currently, there is no specific antiviral therapy against SARS-
CoV-2, the testing of which generally relies on animal infection
models.
Animal models are vital for understanding viral pathogenesis,
vaccine development, and drug screening. Non-human pri-
mates (NHPs) are instrumental for the preclinical evaluation.
However, the application of NHPs is restricted by high costs,
availability, and the complexity of husbandry facilities required.
Thus, appropriate small animal models are essential for
research and antiviral therapeutic development. Mouse models
are popular because their affordability, availability, and clear
genetic backgrounds and have been widely used for studying
pathogenesis of human coronaviruses (Cockrell et al., 2018).
Our previous study demonstrated that SARS-CoV-2 could
use human, bat, or civet ACE2 as a cellular receptor but not
the mouse ACE2 (Zhou et al., 2020). It appears that mice ex-
pressing hACE2 would be a reasonable choice. A transgenic
mouse model (HFH4-hACE2 in C3B6 mice) expressing human
ACE2 has been constructed under the control of a lung ciliated
epithelial cell-specific HFH4/FOXJ1 promoter (Menachery
et al., 2016; Ostrowski et al., 2003). HFH4-hACE2 mice ex-
pressed high levels of hACE2 in the lung, but at varying expres-
sion levels in other tissues, including the brain, liver, kidney,
and gastrointestinal tract. These mice had been used to eval-
uate the pathogenesis of SARS-CoV and bat SARSr-CoVs.
The infected mice that lost >20% body weight maintained
robust replication viral RNA copies in the lung and brain,
although some mice succumbed to lethal encephalitis (Men-
achery et al., 2016; Netland et al., 2008). Here, we evaluated
the infectivity and pathological changes of HFH4-hACE2 mice
following SARS-CoV-2 infection.RESULTS
SARS-CoV-2 Infection Induced the Pathological
Features of Pneumonia in HFH4-hACE2
Transgenic Mice
SARS-CoV-2 uses human ACE2 as its cellular receptor but not
the mouse ACE2 (Hoffmann et al., 2020; Letko et al., 2020;
Zhou et al., 2020). To better study the pathogenesis of
SARS-CoV-2, we initiated an experimental infection using
HFH4-hACE2 (here after hACE2) transgenic mice. The
HFH4-hACE2 mice were intranasally infected with 3 3 104
TCID50 virus each and sacrificed to collect tissue and blood
samples at 1, 3, 5, and 7 days post-infection (DPI) (Figure 1A).
Four mice (two males and two females) were used as control
animals. In the infected group, four mice were excluded for
endpoint data analysis, in which two failed to be infected
(negative for viral RNA in all tissues), and another two died re-
sulting from surgical complications (Table S1). Mouse periph-
eral blood was used for routine blood and biochemistry
analysis.
There were no visible clinical signs during the initial 3 days of
infection except in one male (G-D5-M2) that showed respiratory
distress on day 2 but later recovered (Table S1). Mice showed
two distinct clinical phenotypes from 4 DPI. One mouse (G-D5-
M3) was found dead 4 DPI, and two lost weight 4 DPI and
were humanely euthanized 5 DPI. The remaining mouse began
to loseweight 6 DPI andwas humanely euthanized 7DPI. In total,
these four mice showed significant body weight decreases from
days 4 to 6 and generated noticeable respiratory distress and
neurological symptoms before death or humane euthanization.
All other mice survived to the endpoint without evident symp-
toms (Table S1; Figure 1B).
White blood cell (WBC) analysis indicated that the levels of
most neutrophils and monocytes began to increase in theCell 182, 50–58, July 9, 2020 51
Figure 2. Pathological Changes in HFH4-
hACE2 Mouse Lung after SARS-CoV-2
Infection
Three to six euthanizedmice were used to examine
the pathological changes in the lungs 1, 3, 5, and 7
DPI, respectively.
(A) Mock-infected mice lacked lesions.
(B and C) Mouse lung 1 DPI showed multifocal
lesion (B) with lymphocyte and macrophage infil-
tration (C, red arrow) and fibrin exudation (C, black
arrow).
(D and G) Moderate interstitial pneumonia was
observed 3 DPI with hyaline membrane formation
(D, green arrow), inflammatory infiltration (G, red
arrow), and fibrin exudation (G, black arrow).
(E, F, H, I, J–N) Mild peri-bronchial and peri-
vascular infiltration were observed 5 DPI (E and H)
and 7 DPI (J and M). Some infected mice 5 DPI (F),
7 DPI (K), and at death (L) suffered severe pneu-
monia with blocked terminal bronchioles, fi-
broplasia or organization, and hyaline membrane
formation (I, green arrow; O, red arrow). Alveolar
necrosis (I, N, and O, black arrow) and hyaline
thrombus (N, red arrow) were observed in severely
infected lungs. Martius Scarlet Blue (MSB) staining
was performed to staining fibrin in the lung.
(P–R) Mock-infected mice served as control (P).
Severely infected mice (Q) show hyaline mem-
brane (R, green arrow) and hyaline thrombus (R,
black arrow). Images were collected using a Pan-
noramic MIDI system.
Scale bar: 500 mm (A, B, D–F, J–L, P, and Q) and
100 mm (C, G–I, M–O, and R).
See also Figure S2.
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Articleperipheral blood at day 1, peaked at day 3, and decreased 5 and
7 DPI in the infected group, compared with those of control mice
(Figure S1). The infected mice demonstrated a reduced ratio of
lymphocytes 1 DPI. However, lymphocytes ratio recovered,
beginning on 3 DPI. All the dying mice (dead or lost >20%
body weigh) showed significantly decreased lymphocyte
numbers, which is one of the key clinical hallmarks of COVID-
19 patients (Wang et al., 2020). Five mice showed significantly
higher levels of creatine kinase compared with those of the con-
trol group, which may be linked to muscle fatigue, soreness, or
myocarditis (Table S2). The deceased mice showed higher
aspartate transaminase and creatine kinase levels than the con-
trol group. These data suggested that SARS-CoV-2-infected
mice generate symptoms that partly resembled human infection
symptoms (Chen et al., 2020; Guan et al., 2020; Huang et al.,
2020; Wang et al., 2020).52 Cell 182, 50–58, July 9, 2020We then used histological assays to
check whether these mice acquired
pneumonia. The left lobe of infected
mice was fixed, sectioned, and stained
with hematoxylin and eosin. A similar
sample from one healthy mouse was
used as a negative control. Pathological
sections showed different levels of pneu-
monia throughout the infection course.At 1 DPI, some minor changes were observed in the lung tissues
of infected mice, including minor multifocal lesions, a few alve-
olar walls thickened with monocyte and lymphocyte infiltration,
and increased numbers of macrophages and lymphocytes in
some alveolar spaces with minor exudation of fibrin (Figures
2B and 2C) compared with those in the control (Figure 2A). Mod-
erate interstitial pneumonia appeared at 3 DPI, including multi-
focal lesions, increased inflammatory cells (lymphocytes and
monocytes) at peri-bronchial and peri-vascular infiltration and
fibroblast hyperplasia with exudation of fibrin and protein edema
in some alveoli (Figures 2D and 2G). Two distinct categories were
observed after 5 DPI. Eight mice (72.7%) only show mild peri-
bronchial and peri-vascular infiltration at 5 DPI (Figures 2E and
2H) and 7 DPI (Figures 2J and 2M), while the other three
(27.3%) suffered from more severe pneumonia. In the latter
category, the mouse lungs showed consistently massive
Figure 3. Virus Quantification and Antigen
Detection in Mice after SARS-CoV-2 Infec-
tion
(A–D) Viral RNA was quantified using RT-qPCR in
mouse tissues collected 1, 3, 5, and 7 DPI. The
virus was detected in the mouse lung (A), eyes (B),
heart (C), and brain (D).
(E) Viral antigen was detected by anti-Rp3-CoV N
protein polyclonal antibody (red) in lung bronchi
and alveoli collected 1 DPI (G-D1-5) (E). Images
were collected using FV1200 confocal micro-
scopy. Scale bar is 200 mm.
See also Figures S3, S4, and S5 and Table S3.
ll
Articleperi-bronchial and peri-vascular mixed inflammatory cell infiltra-
tion, fibroplasia or organization, congestion, edema with hyaline
membrane formation with some blocked terminal bronchioles,
and dissolved and necrosis in some alveolar cells at 5 DPI (Fig-
ures 2F and 2I), 7 DPI (Figures 2K and 2N), and upon death (Fig-
ures 2L and 2O). Quantitative pathological scoring showed the
same trends with the hematoxylin-eosin (H&E) pathology obser-
vation (Figure S2). Hyaline thrombus and fibrin were also
observed in the lungs followingMartius Scarlet Blue (MSB) stain-
ing of the tissue samples (Figures 2Q and 2R) compared with the
control (Figure 2P). Since higher creatine kinase may result from
myocardial or muscle damage, we examined the histology of
heart tissue. The heart tissues of infected mice showed edema
in some cardiomyocytes and several necrotic myocytes (Fig-
ure S3B) compared with the control (Figure S3A). Takentogether, SARS-CoV-2 infection success-
fully induced pneumonia in hACE2 mice,
and the histological features of the lung
are very similar to severe patients (Xu
et al., 2020).
Tissue Tropism of SARS-CoV-2 in
Infected Mice
To better understand viral replication in
hACE2 mice, viral RNA was quantified
by RT-qPCR in different tissues from
mice euthanized at 1, 3, 5, and 7 DPI (Fig-
ures 3A–3D). The viral nucleic acid was
detected in all lungs from 1DPI and slowly
increased until 5 DPI and then decreased
beginning 7 DPI (Figure 3A). We also
found low viral RNA copies in the eyes
and hearts in eight and two infected
mice, respectively (Figures 3B and 3C).
No viral RNA was detected in other or-
gans. Viral antigens were detected in
bronchial epithelial cells and alveolar cells
of the lungs using immunohistological as-
says with cross-reactive antibody that
has been used for SARS-CoV-2 detection
previously (Zhou et al., 2020) (Figure 3E).
Notably, four of the animals demon-
strated SARS-CoV-2 neuroinvasion of
the brain but only in the deceased mice(Figure 3D). However, the exact details and mechanisms regu-
lating SARS-CoV-2 neuroinvasion remain unclear, as this phe-
nomenon has been previously described with this mouse model
(Menachery et al., 2016). We then tried to re-isolate SARS-CoV-2
from infected animals. We inoculated Vero E6 cells with infected
mouse (G-D7-M1) lung and brain homogenate supernatant and
observed a noticeable cytopathic effect (CPE) in the infected
cells (Figures S4B and S4C) compared with the control (Fig-
ure S4A). The re-isolated virus from lung and brain of G-D7-M1
was confirmed by indirect imunofluorescence assays (IFAs)
and genome sequencing (Figures S4D–S4F; Table S3). The
lung isolates indicated two mutations, C14554T (nsp13, L372F)
and C23525T (spike, H644Y), compared with the genome of
SARS-CoV-2-WIV04 (GISAID: EPI_ISL_402124). The mutation
at nsp13 was unique compared with published viral sequencesCell 182, 50–58, July 9, 2020 53
Figure 4. Experiment Scheme and Mortality
of HFH4-hACE2 Mice after SARS-CoV-2
Infection
Six hACE2mice (four males and two females) were
intranasally infected with 3 3 104 TCID50 SARS-
CoV-2. Body weights and survival were monitored.
Three survived mice were observed at 21 days.
Then, the three surviving mice and another three
healthy mice were intranasally infected with 7 3
105 TCID50 SARS-CoV-2.
(A) The number in the parenthesis indicates the DPI
of reinfection.
(B) Body weights and survival were monitored
every day. Body weights decreased quickly,
beginning at 4 DPI and led to death, or mice sur-
vived in the absence of significant body weight
decreases.
(C) Three of four male mice died after infection,
while two females survived.
Error bars indicate the standard error.
See also Table S4.
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Articleidentified by online BLAST. The mutation in the spike gene was
located at the end of the S1 region of the spike gene. This muta-
tion was identified using BLAST in SARS-CoV-2 genome
sequence isolated from a patient from the United States (Gen-
Bank: MT163720). The brain isolates exhibited only one muta-
tion, C23525T (H644Y), at the S1 region of the spike gene. The
viral titers in the infected lung ranged from 9.4 3 103 to 9.1 3
105TCID50 per gram of tissue, as determined by serial dilution
of VeroE6 cell lines (Figure S5). Conclusively, SARS-CoV-2
mainly replicated in mouse lung, although it may also target
the brain, heart, and eyes of hACE2 mice. Brain infections
were only observed in the deceased mice, suggesting that neu-
roinvasion is sporadic in this model and likely represents the
cause of death. Similar findings have been reported in other
transgenic mouse models infected with SARS-CoV (McCray
et al., 2007; Menachery et al., 2016).
Surviving Mice Were Resistant to Re-challenge with a
High Dose of SARS-CoV-2
We next evaluated whether this hACE2 mouse model can be
used as a platform for testing the performance of therapeutics
against SARS-CoV-2 infection. We designed an experiment to
test whether mice surviving SARS-CoV-2 infection developed
resistance to reinfection (Figure 4A). Six mice were infected us-
ing identical viral doses via the same route of infection at the
same time with the infection group. Upon infection, three mice
died 6 DPI. All the deceased mice were male, with total mortality
of 50% (3/6). In general, there were two infection outcomes,
those that lost more than 20% body weight from 4 or 5 DPI
and died eventually, or those that lost less than 10% of body
weight and survived (Figures 4B and 4C). Similarly, all deceased
mice generated noticeable neurological symptoms before death.
Three mice, onemale and two females who survived the infec-
tion, were observed for 21 days. These mice generated anti-
bodies against SARS-CoV-2 that could neutralize 100 TCID50 vi-54 Cell 182, 50–58, July 9, 2020ruses at dilutions of 1:10 to 1:40 (Table S4). We then intranasally
infected the three SARS-CoV-2 survivors and another three
healthy mice with 7 3 105 TCID50 virus/each. All previous survi-
vors also survived the second infection. At the same time, two of
the three naive-infected mice demonstrated rapid bodyweight
loss from 4 to 5 DPI with a male and female animal dead at 4
DPI and 5 DPI, respectively (Figures 5A and 5B). All mice were
euthanized at 5 DPI to evaluate viral titers and pathologic
changes in the lung and brain tissues. Survivors had markedly
lower viral RNA copies in the lung and did not present any evi-
dence of neuroinvasion compared with those of the naive-in-
fected animals (Figure 5C). Histopathology of the lungs of the
re-infected survivor cohort showed moderate inflammatory infil-
tration. In contrast, the peri-branchial and peri-vascular inflam-
mation infiltration, hyaline membrane formation, and some
blocked terminal bronchioles were observed in the naive-in-
fected group (Figures 5D and 5E). Limited viral antigen was de-
tected in the lung and brain tissues of the surviving cohort of
mice compared with that of the naive infection group (Figures
5F–5I). The deceased mice showed systemic infection due to
the high viral dose challenge (Table S5). These data demonstrate
that pre-exposure to SARS-CoV-2 may protect mice from a le-
thal SARS-CoV-2 reinfection, which underscores the values of
this model for future therapeutic studies.
DISCUSSION
As a cost-effective and easily manipulated animal model, mice
are widely used in biomedical research. Various genetically
modified mice have been generated to meet the demands of
different projects. Wild-type mice have low levels of ACE2
expression, which limits their use as an infection model for
SARSr-CoVs, which use ACE2 as a receptor. Previous studies
indicated that HFH4-hACE2 mice are susceptible to SARS-
CoV and bat SARSr-CoV WIV1 infection (Menachery et al.,
Figure 5. Previous Infection Protected Mice
from a Higher Dose of Virus Reinfection
Three surviving mice 21 DPI and three previously
mock-infected mice were infected with 7 3 105
TCID50 SARS-CoV-2 at 21 DPI, respectively.
(A and B) Body weights (A) and survival outcomes
(B) were monitored for up to 5 days.
(C) Mice were euthanized 5 DPI, and the viral loads
were measured using RT-qPCR.
(D) Naive-infected mouse lung showed peri-bron-
chial and peri-vascular infiltration and edema with
hyaline membrane formation.
(E) In contrast, previously challenged mice pre-
sented mild peri-bronchial and peri-vascular infil-
tration.
(F–I) Viral antigen was widely present in the naive-
infected mouse lung (F) and brain (H) but barely
observed in previously challenged mouse lung (G)
and brain (I).
Error bars indicate the standard error. ND, not
detected. Scale bar: 500 mm (D and E), 100 mm (F
and G), and 200 mm (H and I).
See also Tables S4 and S5.
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Article2016), suggesting that this model can be used to evaluate the
pathogenicity of all SARSr-CoVs using ACE2 as a receptor. In
this study, we successfully established a SARS-CoV-2 infection
model using these transgenic mice. In our results, the infected
mice had two different outcomes, recovery and death. Signifi-
cant weight loss was only observed in dead and severely
diseasedmice. Thus, weight loss could serve as a good indicator
for monitoring disease progression. Our results provide strong
evidence that SARS-CoV-2 infection could cause typical intersti-
tial pneumonia in hACE2-expressingmice and that progeny virus
could be re-isolated from diseased animal tissues.
COVID-19 patients commonly exhibit pneumonia with typical
signs including fever, cough, dyspnea, and bilateral lung in-
filtration (Guan et al., 2020). Biopsy of the lungs showed
evident desquamation of pneumocytes and hyaline membrane
formation from one patient (Xu et al., 2020). After SARS-CoV-2
infection, the hACE2-experssing mice showed apparent inter-
stitial pneumonia with inflammatory cell infiltration. Severe
pneumonia in mice was accompanied by fibroplasia,
organization, congestion, and edema with hyaline membraneformation. Some alveolar cells were dis-
solved and necrotic, and some terminal
bronchioles were blocked, which simu-
lated the pathological findings in
COVID-19 patients (Xu et al., 2020). Dur-
ing routine blood examination, lympho-
penia is a common feature in COVID-19
patients, and some patients had high-
level aspartate amino transferase (AST)
and creatine kinase (CK) (Chen et al.,
2020; Guan et al., 2020). The blood
routine examination results in SARS-
CoV-2-infected mice were not entirely
consistent with human patients, while
the apparent lymphopenia was observedonly in the dying mice. In our mouse model, the male mice
showed a much higher death rate than the female mice, which
partially reflects the observation infection outcome in humans
(Channappanavar et al., 2017; WHO, 2020). Gender-based sus-
ceptibility differences have been reported in SARS-CoV-in-
fected mice, which demonstrates that the male mice are
more susceptible to SARS-CoV infection than the female
mice (Channappanavar et al., 2017). Compared with SARS-
CoV infection, HFH4-hACE2 mice infected with SARS-CoV-2
showed lower mortality rate but comparable viral titers in the
lung tissues which may partially reflect the lower mortality in
SARS-CoV-2 patients.
We also demonstrated that the lung is the primary target of
this virus, although the eye, heart, and brain could also be in-
fected. In human cases, it has been suspected that SARS-
CoV or SARS-CoV-2 could also attack the eye, heart, and
brain; however, only limited data are available (Gu et al.,
2005; Li et al., 2020b; Lu et al., 2020; Xu et al., 2005). Our study
cautioned that special care should be taken for these viral tar-
gets, especially as the brain and eyes can be persistentlyCell 182, 50–58, July 9, 2020 55
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Articleinfected by other acute RNA viruses, such as Ebola virus
(Shantha et al., 2018). There are few reports about organ
tropism of virus infection in the patients of COVID-19, but mul-
tiple organ infections have been reported in SARS patients (Gu
et al., 2005). In our mouse model, the viral RNA was mainly de-
tected in lung tissues at lower virus titer infection. In compari-
son more positive tissues were detected with higher virus
dose infection, in accordance with the tissue ACE2 expression
in the HFH4-hACE2 mice. Mice experiencing rapid weight loss
were found with high viral RNA in the brain, which is consistent
with the results when HFH4-hACE2 mice were infected by the
bat SARSr-CoV and SARS-CoV (Menachery et al., 2016).
Considering that SARS-CoV has been reported in SARS patient
brains, mouse brain infection after the SARS-CoV-2 challenge
support the potential brain infection in patients (Gu et al.,
2005; Menachery et al., 2016; Xu et al., 2005). Recently, virus
was isolated from ocular fluids of SARS-CoV-2 patients (Cola-
vita et al., 2020), which confirms our finding in mouse model
and implies a potential eye-based infection and transmis-
sion route.
The surviving mice generated low titers of neutralization an-
tibodies (1:10 to 1:40). The reinfection with much higher titers
of virus (7 3 105 TCID50 SARS-CoV-2) only caused mild pneu-
monia in the surviving mice. In contrast, the naive-infected
mice had severe disease with much higher viral RNA copies
in the lung and brain tissues. It is unclear that the neutralizing
antibody or humoral immunity caused the observed protec-
tion. Future studies are needed to determine whether cellular
immune arms also contribute to the protection from
reinfection.
In summary, a human ACE2 mouse model that partially
simulated the pathology of COVID-19, will be a valuable plat-
form for testing vaccines and other potential therapeutics.
Although there are drawbacks associated with this model,
such as lethal encephalitis, it is also a suitable choice for
studying pathogenesis and therapeutic potential on this model
before the central nervous syndromes. Other strains of mice,
including mice of different ages, which had been previously
tested with SARS-CoV and MERS-CoV infections, should
also be verified with SARS-CoV-2 (Gretebeck and Subbarao,
2015; Song et al., 2019). During the revision of this manu-
script, other researchers tested the susceptibility of SARS-
CoV-2 in several animal species. Their results demonstrated
that SARS-CoV-2 could infect hamsters, ferrets, and cats
with resulting mild symptoms but not pigs, chickens, or ducks
(Chan et al., 2020; Shi et al., 2020). The increasing global
spread of SARS-CoV-2 promotes the urgent need for corona-
virus vaccines and therapeutics. The successful establish-
ment of an animal model for COVID-19 pathogenesis will be
valuable for evaluating vaccines and therapeutics to combat
SARS-CoV-2.
Limitations
The HFH4-hACE2 mice showed different susceptibility with the
infection of SARS-CoV-2 based on gender. The LD50 of SARS-
CoV-2 should be determined for different gender mice. The
dead mice showed the brain infection that may not reflect the
pathogenesis of SARS-CoV-2 in humans. Future studies should56 Cell 182, 50–58, July 9, 2020determine the persisting time of virus in infected mice. Aged
mice should be tested the susceptibility of SARS-CoV-2
infection.
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Data and Code Availability
The study did not generate unique datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Virus and Cell lines
The SARS-CoV-2 (IVCAS 6.7512) was isolated using bronchoalveolar lavage fluid sample of patient and was propagated and titrated
in Vero E6 cell lines (Zhou et al., 2020). Vero E6 is a kidney epithelial cell line derived from female African green monkey (ATCC
CRL-1586). Vero E6 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal
bovine serum (FBS, Life Technologies) and 1% Anti-Anti (Invitrogen) at 37C with 5% CO2. Viral titrations were performed with
10-fold serial dilutions in Vero E6 cells. Three days after inoculation, CPE was scored, and the Reed-Muench formula was used to
calculate the TCID50.
HFH4-hACE2 mice
The transgenic mice (HFH4-hACE2 mice) expressing the human ACE2 protein (hACE2) under mixed genetic backgrounds (C3H,
C57BL/6) were obtained fromRalph S. Baric’s lab (Menachery et al., 2016). The HFH4-hACE2mice were bred andmaintained in spe-
cific pathogen free (SPF) environment at the Laboratory Animal Center of Wuhan Institute of Virology, CAS. Twenty-two male and
twelve female mice at eight to ten weeks-old were used in this study. Littermates of the same sex were randomly assigned to
mock, 1, 3, 5, 7 DPI and survival groups. Viral infections were performed in a biosafety level 3 (BSL3) facility in accordance with rec-




Micewere anaesthetised with tribromoethanol (Avertin) (250mg/kg) and intranasally infected with 3*104 TCID50 (for naive infection) or
7*105 TCID50 (for the viral challenge) SARS-CoV-2 in 50 mL DMEM per mouse. The experiments were divided into three groups: the
control group, two males and two females were inoculated with DMEM; the survival monitoring group, four males and two females
were inoculated with the virus; the pathology progression group, sixteen males and eight females were inoculated with the virus (Ta-
ble S1). Accidental death or uninfected mice were excluded from subsequent experiments. Infected mice negative for viral RNA in all
tissues were regarded as a failed infection. Mice were weighted and observed for clinical signs daily throughout the study. Four to six
mice were euthanised at 1, 3, 5 and 7 DPI, and mice presenting more than a twenty percent decrease in body weight were humane
euthanised and considered as dead mice. The details regarding the number of male and female mice in each group are shown in
Table S1 and Table S4. Tissues were harvested, including the blood, heart, liver, spleen, lung, brain, kidney, eyes, genital glands,
and small intestines.
Blood sampling and biochemistry
Blood was collected retro-orbitally and transferred to a blood collection tube containing EDTA to prevent clotting. Cell classifications
were analyzed using aProCyte DxHematology Analyzer (IDEXX) followedwithmanufacturer’s instructions. Plasmawas separated by
centrifugation at 3,000 3 g for 10 min at room temperature and stored at 80C until use. Plasma was collected, diluted 1:6 with
phosphate-buffered saline (PBS), and tested using Catalyst One (IDEXX) followed with manufacturer’s instructions.
Viral antibody testing and neutralisation assay
All serum samples were heat-inactivated by incubation at 56C for 30 min before use. Mouse plasma (24 mL) was serially two-fold
diluted from 1:10 to 1:1280, then an equal volume of virus solution with 100 TCID50 virus was added and incubated at 37
C for
30 min in a 5% CO2 incubator. Diluted negative sera were mixed with an equal volume of virus solution and were used as a negative
control. After incubation, 50 mL mixtures were inoculated onto monolayer Vero E6 cells in a 96-well plate for 1 h. After removing the
supernatant, the plate was washed twice with DMEM, cells were incubated with DMEM supplemented with 2% FBS for three days.
Each serum concentration was duplicated. Cells were observed for CPE, and neutralising titers were recorded as the final serum
dilution that could neutralise all inoculated wells.
Extraction of viral RNA and quantitative RT-PCR
Mouse organs were homogenized in RNALater, and viral RNA was isolated using the QIAamp  96 Virus QIAcube  HT kit
(QIAGEN). Twomicroliters of RNAwere used as a template for the amplification of selected genes by real-time quantitative PCRusinge2 Cell 182, 50–58.e1–e3, July 9, 2020
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ArticleHiSxript  II One step qRT-PCR SYBR Green Kit (Vazyme). Average values from duplicates of each gene were used to calculate
the viral genomic copies. The primers based on the SARS-CoV-2 S gene were designed as: RBD-qF1: 50- CAATGGTTTAACAGG
CACAGG-30; RBD-qR1: 50- CTCAAGTGTCTGTGGATCACG-30. The PCR system was as follows: the 10 mL qPCR reaction mix
contained 5 mL 2 3 One Step SYBR Green mix, 1.9 mL nuclease free water, 0.5 mL One Step SYBR Green Enzyme mix, 0.2 mL
50 3 ROX Reference Dye 1, 0.2 mL of each primer (10 mM) and 2 mL template RNA. Amplification was performed as follows: 50C
for 3 min, 95C for 30 s followed by 40 cycles consisting of 95C for 10 s and 60C for 30 s, and a default melting curve step in
an Step-One Plus Real-time PCR machine (ABI) (Zhou et al., 2020).
Histological Analysis
Lung and brain samples were fixed with 4% paraformaldehyde, paraffin embedded and cut into 3.5-mm sections. Fixed tissue
samples were used for hematoxylin-eosin (H&E) staining and indirect immunofluorescence assays (IFA) for the detection of the
SARS-CoV-2 antigen. For routine histology, tissue sections were stained with H&E. For IFA, slides were deparaffinised and rehy-
drated, followed by 15-min heat-induced antigen retrieval with EDTA pH 8.0 in a microwave oven. The slides were washed with
PBS/0.02% Triton X-100 then blocked with 5% BSA at room temperature for 1 h. A primary antibody (rabbit anti-RP3-CoV N protein
polyclonal antibody, 1:500, made in-house) was added dropwise to the sections and then washed in PBS. After the slides were
slightly dried, tissues were covered with Cy3-conjugated goat-anti-rabbit IgG (Abcam, ab6939) at 1:200 dilution. After washing in
PBS, slides were stained with DAPI (Beyotime) at 1:100 dilution. For MSB staining, fixed tissue sections were stained with hyposulfite
solution, Celestine blue, and hematoxylin for 3-5 min, respectively. After acidic differentiation with acid alcohol, the sections were
stained with Martius Yellow solution, carmoisine solution, phosphotungstic acid solution, and aniline blue staining solution, respec-
tively. Tissue sections were rinsed with 1% acetic acid and then dehydrated, cleared, and mounted with neutral gum. The image in-
formation was collected using a Pannoramic MIDI system (3DHISTECH, Budapest) and FV1200 confocal microscopy (Olympus).
Virus isolation and sequencing
Infected lung and brain tissues from euthanised mice were homogenized with DMEM, and the supernatant was used for virus isola-
tion. A total of 200 mL supernatant was inoculated onto monolayer Vero E6 cells in a 24-well plate. After 1 h inoculation, the
supernatant was removed and replaced with fresh DMEM containing 2% FBS plus 1% Anti-Anti. CPE was monitored daily, and
the supernatant was clarified from debris and subjected to viral RNA extraction after the onset of CPE. Viral RNA copies were quan-
tified by qPCR, and viral antigens were detected using IFA. Images were collected by EVOS M5000 (Thermo). The Next-generation
sequencing (NGS) was performed by using IlluminaMiSeq 3000 sequencers and the sequences were analyzed by Geneious10.2.6
for Windows (Zhou et al., 2020).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Statistical analyses were performed using PRISM 8.0.2 for Windows (GraphPad). Significant differences between groups were
determined using a two-way analysis of variance (ANOVA). For contrasting two experimental groups, two-tailed Student’s t tests
were performed to determine significant differences. Statistical significant: *p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.Cell 182, 50–58.e1–e3, July 9, 2020 e3
Supplemental Figures
Figure S1. White Blood Cells in Peripheral Blood, Related to Figure 1 and Table S2
Peripheral blood was collected from mock-infected (n = 4) and, virus-infected mice 1 (n = 5), 3 (n = 3), 5 (n = 4) and 7 (n = 4) DPI and three dying (one from the
infected group and the other two from the survival test group) mice 6 DPI. TheWBC population wasmeasured using ProCyte Dx Hematology Analyzer. Error bars




Figure S2. Clinical Scores of Lung Pathology, Related to Figure 2
Quantitative scoring of pathology of lung tissues from infected mice 1 (n = 5), 3 (n = 3), 5 (n = 5) and 7 (n = 5) DPI. Error bars indicate the standard error.
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Figure S3. Pathological Changes of HFH4-hACE2 Mouse Heart after SARS-CoV-2 Infection, Related to Figure 3
Mock-infectedmice (A). Infectedmice showed edema in some cardiomyocytes, lymphocyte proliferation (cyan arrow), several necroticmyocytes (red arrow), and
vascular edema (black arrow) (B). Scale bar is 200 mm.
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Figure S4. Virus Isolation from Infected Mouse Lung and Brain Tissues, Related to Figure 3 and Table S3
Infected mouse lung and brain tissues were homogenized with DMEM, and the supernatant was used to infect Vero E6 cells. CPE was observed in cells infected
by the homogenized supernatant of lung (B) and brain (C) but not in mock-infected cells (A). Viral antigen was detected in the cells infected by homogenized
supernatant of the lung (E) and brain (F) but not in mock-infected cells (D). Scale bar: 1000 mm (A, B, C) and 200 mm (D, E, F).
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Figure S5. Viral Titers in Lung Tissue of Mice after SARS-CoV-2 Infection, Related to Figure 3
Viral titers were determined by the TCID50 assay using VeroE6 cells formouse lung tissues collected 1 (n = 3), 3 (n = 3) and 5 (n = 4) DPI. The lung samples collected
7 DPI were used for virus isolation. Error bars indicate the standard error.
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